ALXN News and Press, Alexion Pharmaceuticals Inc. From 07/24/19

Alexion Pharmaceuticals (NASDAQ: ALXN ): Q2 Non-GAAP EPS of $2.64 beats by $0.30 ; GAAP EPS of $2.04 beats by $0.28 . More news on: Alexion Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

2Q19 total revenues of $1,203.3 million, a 15 percent increase over 2Q18 and a 23 percent volume increase 2Q19 GAAP diluted EPS of $2.04; non-GAAP diluted EPS of $2.64 Received 3 regulatory approvals - SOLIRIS ® (eculizumab) for adults with neuromyelitis optica spectrum...

ALXN , ANTM , APH , ARCH , BA , BCO , BKU , BOKF , BPOP , BSX , CAT , CHKP , CSTM , DTE , EVR , FCFS , FCX , FLIR , FSV , GD , GWW , HLT , IART , IQV , KNX , LAD , MDCO , MHO , MKTX , MLCO , NDAQ , NEE , NOC , NSC , NTRS , OC , PB , RES , ROL , SC , ...

Rigel Pharmaceuticals' ( RIGL ) Tavalisse, launched in mid-2018, is experiencing sales growth but competitors exist that could potentially reduce peak sales. RIGL's partnered pipeline provides a source of potentially good news to offset any bad news regarding advances from RIGL's competitors...

Alexion Pharmaceuticals (Nasdaq:ALXN) today announced that the Company will report its financial results for the second quarter ended June 30, 2019 before the US financial markets open on July 24, 2019. Following the release of the financial results, Alexion management will conduct a conferen...

Alexion Pharmaceuticals ( ALXN ) is up over 30% this year, but due to a dip at the end of 2018, the stock isn't in uncharted territory. Current investors may be frustrated with what amounts to volatile but nonetheless sideways trading and considering if 2019 will offer anything different. This...

Alexion Pharmaceuticals ( ALXN ) is an innovative, commercial-stage pharmaceutical company specializing in therapies for rare, hard-to-treat diseases. It has a market cap of about $29 billion. The stock has not moved much, expecting volatility, since early 2014, but revenue and earnings have r...

- ULTOMIRIS is the first approved, long-acting complement inhibitor for PNH, administered every other month, reducing the treatment burden for patients - - ULTOMIRIS has the potential to become the new standard of care for both complement inhibitor-naïve patients and patients swit...

- At 48 weeks, 98% of patients treated with SOLIRIS were relapse free compared to 63% of patients receiving placebo - - SOLIRIS is the first and only FDA approved treatment for this rare, severe, condition that attacks the central nervous system without warning - Alexion Pharmace...

Noteworthy events during the week of June 23 - 29 for healthcare investors. More news on: Palatin Technologies, Inc., Calyxt, Inc., Acer Therapeutics Inc., Healthcare stocks news, , Read more ...